Phage display screening of therapeutic peptide for cancer targeting and therapy

doi:10.1007/s13238-019-0639-7

Protein Cell

2019, Vol. 10

Issue (11) : 787-807 https://doi.org/10.1007/s13238-019-0639-7

REVIEW

Phage display screening of therapeutic peptide for cancer targeting and therapy

Phei Er Saw¹, Er-Wei Song^1,²(

)

¹. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
². Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China

Download: PDF(1388 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Recently, phage display technology has been announced as the recipient of Nobel Prize in Chemistry 2018. Phage display technique allows high affinity target-binding peptides to be selected from a complex mixture pool of billions of displayed peptides on phage in a combinatorial library and could be further enriched through the biopanning process; proving to be a powerful technique in the screening of peptide with high affinity and selectivity. In this review, we will first discuss the modifications in phage display techniques used to isolate various cancer-specific ligands by in situ, in vitro, in vivo, and ex vivo screening methods. We will then discuss prominent examples of solid tumor targeting-peptides; namely peptide targeting tumor vasculature, tumor microenvironment (TME) and overexpressed receptors on cancer cells identified through phage display screening. We will also discuss the current challenges and future outlook for targeting peptidebased therapeutics in the clinics.

Keywords phage display tumor targeting peptide tumor vasculature tumor microenvironment tumor stromal cells over-expressed receptor

Corresponding Author(s): Er-Wei Song

Issue Date: 05 December 2019

Cite this article:

Phei Er Saw,Er-Wei Song. Phage display screening of therapeutic peptide for cancer targeting and therapy[J]. Protein Cell, 2019, 10(11): 787-807.

URL:

https://academic.hep.com.cn/pac/EN/10.1007/s13238-019-0639-7
https://academic.hep.com.cn/pac/EN/Y2019/V10/I11/787

1	LF Abrahao-Machado, C Scapulatempo-Neto (2016) HER2 testing in gastric cancer: an update. World J Gastroenterol 22:4619–4625 https://doi.org/10.3748/wjg.v22.i19.4619
2	S Ai, J Duan, X Liu, S Bock, Y Tian, Z Huang (2011) Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells. Mol Pharm 8:375–386 https://doi.org/10.1021/mp100243j
3	M Albrecht, H Renneberg, G Wennemuth, O Moschler, M Janssen, G Aumuller, L Konrad (1999) Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance. Histochem Cell Biol 112:51–61 https://doi.org/10.1007/s004180050391
4	D AlDeghaither, BG Smaglo, LM Weiner (2015) Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol 55(Suppl 3):S4–20 https://doi.org/10.1002/jcph.407
5	RT Altstock, GY Stein, JH Resau, I Tsarfaty (2000) Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model. Cytometry 41:155–165 https://doi.org/10.1002/1097-0320(20001101)41:3<155::AID-CYTO1>3.0.CO;2-4
6	H Amaya, N Tanigawa, C Lu, M Matsumura, T Shimomatsuya, T Horiuchi, R Muraoka (1997) Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 119:227–235 https://doi.org/10.1016/S0304-3835(97)00280-2
7	W Arap, R Pasqualini, E Ruoslahti (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380 https://doi.org/10.1126/science.279.5349.377
8	W Arap, W Haedicke, M Bernasconi, R Kain, D Rajotte, S Krajewski, HM Ellerby, DE Bredesen, R Pasqualini, E Ruoslahti (2002a) Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 99:1527–1531 https://doi.org/10.1073/pnas.241655998
9	W Arap, MG Kolonin, M Trepel, J Lahdenranta, M Cardo-Vila, RJ Giordano, PJ Mintz, PU Ardelt, VJ Yao, CI Vidalet al. (2002b) Steps toward mapping the human vasculature by phage display. Nat Med 8:121–127 https://doi.org/10.1038/nm0202-121
10	A Argiris, CX Wang, SG Whalen, MP DiGiovanna (2004) Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10:1409–1420 https://doi.org/10.1158/1078-0432.CCR-1060-02
11	A Armulik, A Abramsson, C Betsholtz (2005) Endothelial/pericyte interactions. Circ Res 97:512–523 https://doi.org/10.1161/01.RES.0000182903.16652.d7
12	SA Arnold, HA Loomans, T Ketova, CD Andl, PE Clark, A Zijlstra (2016) Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis 33:29–44 https://doi.org/10.1007/s10585-015-9754-x
13	M Augsten (2014) Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol 4:62 https://doi.org/10.3389/fonc.2014.00062
14	YK Bae, A Kim, MK Kim, JE Choi, SH Kang, SJ Lee (2013) Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum Pathol 44:2028–2037 https://doi.org/10.1016/j.humpath.2013.03.006
15	S Bao, Q Wu, RE McLendon, Y Hao, Q Shi, AB Hjelmeland, MW Dewhirst, DD Bigner, JN Rich (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760 https://doi.org/10.1038/nature05236
16	A Barve, W Jin, K Cheng (2014) Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release 187:118–132 https://doi.org/10.1016/j.jconrel.2014.05.035
17	J Baselga, SM Swain (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463–475 https://doi.org/10.1038/nrc2656
18	M Benekli, H Baumann, M Wetzler (2009) Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 27:4422–4432 https://doi.org/10.1200/JCO.2008.21.3264
19	G Bergers, K Javaherian, KM Lo, J Folkman, D Hanahan (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808–812 https://doi.org/10.1126/science.284.5415.808
20	NA Bhowmick, EG Neilson, HL Moses (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337 https://doi.org/10.1038/nature03096
21	M Binnewies, EW Roberts, K Kersten, V Chan, DF Fearon, M Merad, LM Coussens, DI Gabrilovich, S Ostrand-Rosenberg, CC Hedricket al. (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541–550 https://doi.org/10.1038/s41591-018-0014-x
22	H Birkedal-Hansen (1995) Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7:728–735 https://doi.org/10.1016/0955-0674(95)80116-2
23	T Boehm, J Folkman, T Browder, MS O’Reilly (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404–407 https://doi.org/10.1038/37126
24	RJ Boohaker, MW Lee, P Vishnubhotla, JM Perez, AR Khaled (2012) The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 19:3794–3804 https://doi.org/10.2174/092986712801661004
25	DG Bostwick, A Pacelli, M Blute, P Roche, GP Murphy (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261 https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S
26	DP Bottaro, JS Rubin, DL Faletto, AM Chan, TE Kmiecik, GF Vande Woude, SA Aaronson (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802–804 https://doi.org/10.1126/science.1846706
27	LT Brinton, DK Bauknight, SS Dasa, KA Kelly (2016) PHASTpep: analysis software for discovery of cell-selective peptides via phage display and next-generation sequencing. PLoS ONE 11: e0155244 https://doi.org/10.1371/journal.pone.0155244
28	PC Brooks, S Stromblad, LC Sanders, TL von Schalscha, RT Aimes, WG Stetler-Stevenson, JP Quigley, DA Cheresh (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683–693 https://doi.org/10.1016/S0092-8674(00)81235-0
29	R Bueno, K Appasani, H Mercer, S Lester, D Sugarbaker (2001) The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 121:225–233 https://doi.org/10.1067/mtc.2001.111176
30	MA Burg, R Pasqualini, W Arap, E Ruoslahti, WB Stallcup (1999) NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 59:2869–2874
31	HJ Burstein (2005) The distinctive nature of HER2-positive breast cancers. N Engl J Med 353:1652–1654 https://doi.org/10.1056/NEJMp058197
32	B Chan, S Sinha, D Cho, R Ramchandran, VP Sukhatme (2005) Critical roles of CD146 in zebrafish vascular development. Dev Dyn 232:232–244 https://doi.org/10.1002/dvdy.20220
33	SS Chang, VE Reuter, WD Heston, PB Gaudin (2001) Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 57:1179–1183 https://doi.org/10.1016/S0090-4295(01)00983-9
34	DK Chang, CT Lin, CH Wu, HC Wu (2009) A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS ONE 4:e4171 https://doi.org/10.1371/journal.pone.0004171
35	J Chen, Y Yao, C Gong, F Yu, S Su, J Chen, B Liu, H Deng, F Wang, L Linet al. (2011) CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19:541–555 https://doi.org/10.1016/j.ccr.2011.02.006
36	DS Chen, BA Irving, FS Hodi (2012) Molecular pathways: nextgeneration immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18:6580–6587 https://doi.org/10.1158/1078-0432.CCR-12-1362
37	R Chiquet-Ehrismann (1990) What distinguishes tenascin from fibronectin? FASEB J 4:2598–2604 https://doi.org/10.1096/fasebj.4.9.1693347
38	HS Cho, K Mason, KX Ramyar, AM Stanley, SB Gabelli, DW Jr Denney, DJ Leahy (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756–760 https://doi.org/10.1038/nature01392
39	M Cieslewicz, J Tang, JL Yu, H Cao, M Zavaljevski, K Motoyama, A Lieber, EW Raines, SH Pun (2013) Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc Natl Acad Sci U S A 110:15919–15924 https://doi.org/10.1073/pnas.1312197110
40	AT Collins, PA Berry, C Hyde, MJ Stower, NJ Maitland (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951 https://doi.org/10.1158/0008-5472.CAN-05-2018
41	EK Colvin (2014) Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol 4:137 https://doi.org/10.3389/fonc.2014.00137
42	CS Cooper, M Park, DG Blair, MA Tainsky, K Huebner, CM Croce, GF Vande Woude (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29–33 https://doi.org/10.1038/311029a0
43	J Denekamp (1993) Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181–196 https://doi.org/10.1259/0007-1285-66-783-181
44	MF Di Renzo, RP Narsimhan, M Olivero, S Bretti, S Giordano, E Medico, P Gaglia, P Zara, PM Comoglio (1991) Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6:1997–2003
45	MF Di Renzo, M Olivero, S Ferro, M Prat, I Bongarzone, S Pilotti, A Belfiore, A Costantino, R Vigneri, MA Pierottiet al. (1992) Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7:2549–2553
46	SE Duff, M Jeziorska, DD Rosa, S Kumar, N Haboubi, D Sherlock, ST O’Dwyer, GC Jayson (2006) Vascular endothelial growth factors and receptors in colorectal cancer: implications for antiangiogenic therapy. Eur J Cancer 42:112–117 https://doi.org/10.1016/j.ejca.2005.09.018
47	M Ebert, M Yokoyama, H Friess, MW Buchler, M Korc (1994) Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 54:5775–5778
48	M Essler, E Ruoslahti (2002) Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A 99:2252–2257 https://doi.org/10.1073/pnas.251687998
49	M Fan, X Liang, D Yang, X Pan, Z Li, H Wang, B Shi (2016) Epidermal growth factor receptor-targeted peptide conjugated phospholipid micelles for doxorubicin delivery. J Drug Target 24:111–119 https://doi.org/10.3109/1061186X.2015.1058800
50	N Ferrara, K Alitalo (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359–1364 https://doi.org/10.1038/70928
51	N Ferrara, HP Gerber, J LeCouter (2003) The biology of VEGF and its receptors. Nat Med 9:669–676 https://doi.org/10.1038/nm0603-669
52	M Florek, M Haase, AM Marzesco, D Freund, G Ehninger, WB Huttner, D Corbeil (2005) Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319:15–26 https://doi.org/10.1007/s00441-004-1018-z
53	J Folkman (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186 https://doi.org/10.1056/NEJM197111182852108
54	KR Fontenot, BG Ongarora, LE LeBlanc, Z Zhou, SD Jois, MG Vicente (2016) Targeting of the epidermal growth factor receptor with mesoporphyrin IX–peptide conjugates. J Porphyr Phthalocyanines 20:352–366 https://doi.org/10.1142/S1088424616500115
55	OE Franco, AK Shaw, DW Strand, SW Hayward (2010) Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 21:33–39 https://doi.org/10.1016/j.semcdb.2009.10.010
56	AM Georgoudaki, KE Prokopec, VF Boura, E Hellqvist, S Sohn, J Ostling, R Dahan, RA Harris, M Rantalainen, D Klevebringet al. (2016) Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep 15:2000–2011 https://doi.org/10.1016/j.celrep.2016.04.084
57	H Gerhardt, C Betsholtz (2003) Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314:15–23 https://doi.org/10.1007/s00441-003-0745-x
58	MA Ghert, ST Jung, W Qi, JM Harrelson, HP Erickson, JA Block, SP Scully (2001) The clinical significance of tenascin-C splice variant expression in chondrosarcoma. Oncology 61:306–314 https://doi.org/10.1159/000055338
59	S Ghosh, CA Sullivan, MP Zerkowski, AM Molinaro, DL Rimm, RL Camp, GG Chung (2008) High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 39:1835–1843 https://doi.org/10.1016/j.humpath.2008.06.004
60	RJ Giordano, M Cardo-Vila, J Lahdenranta, R Pasqualini, W Arap (2001) Biopanning and rapid analysis of selective interactive ligands. Nat Med 7:1249–1253 https://doi.org/10.1038/nm1101-1249
61	RJ Goodson, MV Doyle, SE Kaufman, S Rosenberg (1994) Highaffinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci U S A 91:7129–7133 https://doi.org/10.1073/pnas.91.15.7129
62	JR Grandis, JC Sok (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102:37–46 https://doi.org/10.1016/j.pharmthera.2004.01.002
63	CL Green, M Loken, D Buck, HJ Deeg (2000) Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML). Leukemia 14:770–772 https://doi.org/10.1038/sj.leu.2401736
64	C Gutierrez, R Schiff (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135:55–62
65	Z Han, Z Zhou, X Shi, J Wang, X Wu, D Sun, Y Chen, H Zhu, C Magi-Galluzzi, ZR Lu (2015) EDB fibronectin specific peptide for prostate cancer targeting. Bioconjug Chem 26:830–838 https://doi.org/10.1021/acs.bioconjchem.5b00178
66	D Hanahan, J Folkman (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364 https://doi.org/10.1016/S0092-8674(00)80108-7
67	N Hanamura, T Yoshida, E Matsumoto, Y Kawarada, T Sakakura (1997) Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer 73:10–15 https://doi.org/10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4
68	K Harhouri, A Kebir, B Guillet, A Foucault-Bertaud, S Voytenko, MD Piercecchi-Marti, C Berenguer, E Lamy, F Vely, P Pisanoet al. (2010) Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 115:3843–3851 https://doi.org/10.1182/blood-2009-06-229591
69	LC Hartmann, GL Keeney, WL Lingle, TJ Christianson, B Varghese, D Hillman, AL Oberg, PS Low (2007) Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121:938–942 https://doi.org/10.1002/ijc.22811
70	M Hashida, M Nishikawa, F Yamashita, Y Takakura (2001) Cellspecific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev 52:187–196 https://doi.org/10.1016/S0169-409X(01)00209-5
71	MA Hayashi, F Ducancel, K Konno (2012) Natural peptides with potential applications in drug development, diagnosis, and/or biotechnology. Int J Pept 2012:757838 https://doi.org/10.1155/2012/757838
72	C He, S Su, F Chen, D Huang, F Zheng, W Huang, J Chen, X Cui, Q Liu, E Songet al. (2014) Overexpression of PITPNM3 promotes hepatocellular carcinoma cell metastasis. Chin Sci Bull 59:1326–1333 https://doi.org/10.1007/s11434-014-0183-z
73	I Hellstrom, PL Beaumier, KE Hellstrom (1986a) Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci U S A 83:7059–7063 https://doi.org/10.1073/pnas.83.18.7059
74	I Hellstrom, D Horn, P Linsley, JP Brown, V Brankovan, KE Hellstrom (1986b) Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res 46:3917–3923
75	TJ Hemesath, K Stefansson (1994) Expression of tenascin in thymus and thymic nonlymphoid cells. J Immunol 152:422–428
76	HD Hemmati, I Nakano, JA Lazareff, M Masterman-Smith, DH Geschwind, M Bronner-Fraser, HI Kornblum (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100:15178–15183 https://doi.org/10.1073/pnas.2036535100
77	GB Henderson (1990) Folate-binding proteins. Annu Rev Nutr 10:319–335 https://doi.org/10.1146/annurev.nu.10.070190.001535
78	A Heppeler, S Froidevaux, AN Eberle, HR Maecke (2000) Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7:971–994 https://doi.org/10.2174/0929867003374516
79	PC Hermann, SL Huber, T Herrler, A Aicher, JW Ellwart, M Guba, CJ Bruns, C Heeschen (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323 https://doi.org/10.1016/j.stem.2007.06.002
80	W Hindermann, A Berndt, L Borsi, X Luo, P Hyckel, D Katenkamp, H Kosmehl (1999) Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 189:475–480 https://doi.org/10.1002/(SICI)1096-9896(199912)189:4<475::AID-PATH462>3.0.CO;2-V
81	A Hoeben, B Landuyt, MS Highley, H Wildiers, AT Van Oosterom, EA De Bruijn (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549–580 https://doi.org/10.1124/pr.56.4.3
82	PA Horn, H Tesch, P Staib, D Kube, V Diehl, D Voliotis (1999) Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. Blood 93:1435–1437 https://doi.org/10.1182/blood.V93.4.1435
83	M Houimel, P Schneider, A Terskikh, JP Mach (2001) Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor. Int J Cancer 92:748–755 https://doi.org/10.1002/1097-0215(20010601)92:5<748::AID-IJC1258>3.0.CO;2-1
84	PA Humphrey, X Zhu, R Zarnegar, PE Swanson, TL Ratliff, RT Vollmer, ML Day (1995) Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147:386–396
85	D Huntsman, JH Resau, E Klineberg, N Auersperg (1999) Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol 155:343–348 https://doi.org/10.1016/S0002-9440(10)65130-9
86	H Inufusa, M Nakamura, T Adachi, Y Nakatani, K Shindo, M Yasutomi, H Matsuura (1995) Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis. Cancer 75:2802–2808 https://doi.org/10.1002/1097-0142(19950615)75:12<2802::AID-CNCR2820751204>3.0.CO;2-O
87	E Ioachim, A Charchanti, E Briasoulis, V Karavasilis, H Tsanou, DL Arvanitis, NJ Agnantis, N Pavlidis (2002) Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 38:2362–2370 https://doi.org/10.1016/S0959-8049(02)00210-1
88	RK Jain (2001) Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46:149–168 https://doi.org/10.1016/S0169-409X(00)00131-9
89	H Jeon, D Kim, M Choi, S Kang, JY Kim, S Kim, S Jon (2017) Targeted Cancer Therapy Using Fusion Protein of TNFalpha and Tumor-Associated Fibronectin-Specific Aptide. Mol Pharm 14:3772–3779 https://doi.org/10.1021/acs.molpharmaceut.7b00520
90	W Jin, B Qin, Z Chen, H Liu, A Barve, K Cheng (2016) Discovery of PSMA-specific peptide ligands for targeted drug delivery. Int J Pharm 513:138–147 https://doi.org/10.1016/j.ijpharm.2016.08.048
91	W Jung, E Castren, M Odenthal, GF Vande Woude, T Ishii, HP Dienes, D Lindholm, P Schirmacher (1994) Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain. J Cell Biol 126:485–494 https://doi.org/10.1083/jcb.126.2.485
92	T Jyothi (2012) Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012:13 https://doi.org/10.1155/2012/967347
93	T Kajita, Y Ohta, K Kimura, M Tamura, Y Tanaka, Y Tsunezuka, M Oda, T Sasaki, G Watanabe (2001) The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 85:255–260 https://doi.org/10.1054/bjoc.2001.1882
94	OP Kallioniemi, A Kallioniemi, W Kurisu, A Thor, LC Chen, HS Smith, FM Waldman, D Pinkel, JW Gray (1992) ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 89:5321–5325 https://doi.org/10.1073/pnas.89.12.5321
95	R Kalluri, RA Weinberg (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420–1428 https://doi.org/10.1172/JCI39104
96	R Kalluri, M Zeisberg (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401 https://doi.org/10.1038/nrc1877
97	MA Kane, PC Elwood, RM Portillo, AC Antony, V Najfeld, A Finley, S Waxman, JF Kolhouse (1988) Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells. J Clin Invest 81:1398–1406 https://doi.org/10.1172/JCI113469
98	Y Kang, F Wang, J Feng, D Yang, X Yang, X Yan (2006) Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Res 16:313–318 https://doi.org/10.1038/sj.cr.7310039
99	NG Karasseva, VV Glinsky, NX Chen, R Komatireddy, TP Quinn (2002) Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem 21:287–296 https://doi.org/10.1023/A:1019749504418
100	M Kaspar, L Zardi, D Neri (2006) Fibronectin as target for tumor therapy. Int J Cancer 118:1331–1339 https://doi.org/10.1002/ijc.21677
101	A Kebir, K Harhouri, B Guillet, JW Liu, A Foucault-Bertaud, E Lamy, E Kaspi, N Elganfoud, F Vely, F Sabatieret al. (2010) CD146 short isoform increases the proangiogenic potential of endothelial progenitor cells in vitro and in vivo. Circ Res 107:66–75 https://doi.org/10.1161/CIRCRESAHA.109.213827
102	LE Kelemen (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119:243–250 https://doi.org/10.1002/ijc.21712
103	KA Kelly, JR Allport, A Tsourkas, VR Shinde-Patil, L Josephson, R Weissleder (2005) Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 96:327–336 https://doi.org/10.1161/01.RES.0000155722.17881.dd
104	RS Kerbel (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13:31–36 https://doi.org/10.1002/bies.950130106
105	ZA Khan, J Caurtero, YP Barbin, BM Chan, S Uniyal, S Chakrabarti (2005) ED-B fibronectin in non-small cell lung carcinoma. Exp Lung Res 31:701–711 https://doi.org/10.1080/01902140591007236
106	MY Kim, OR Kim, YS Choi, H Lee, K Park, CT Lee, KW Kang, S Jeong (2012a) Selection and characterization of tenascin C targeting peptide. Mol Cells 33:71–77 https://doi.org/10.1007/s10059-012-2214-4
107	S Kim, D Kim, HH Jung, IH Lee, JI Kim, JY Suh, S Jon (2012b) Bioinspired design and potential biomedical applications of a novel class of high-affinity peptides. Angew Chem Int Ed Engl 51:1890–1894 https://doi.org/10.1002/anie.201107894
108	H Kim, Y Lee, IH Lee, S Kim, D Kim, PE Saw, J Lee, M Choi, YC Kim, S Jon (2014) Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin. J Control Release 178:118–124 https://doi.org/10.1016/j.jconrel.2014.01.015
109	H Kim, Y Lee, S Kang, M Choi, S Lee, S Kim, V Gujrati, J Kim, S Jon (2016) Self-assembled nanoparticles comprising aptide-SN38 conjugates for use in targeted cancer therapy. Nanotechnology 27:48LT01 https://doi.org/10.1088/0957-4484/27/48/48LT01
110	G Klein, S Beck, CA Muller (1993) Tenascin is a cytoadhesive extracellular matrix component of the human hematopoietic microenvironment. J Cell Biol 123:1027–1035 https://doi.org/10.1083/jcb.123.4.1027
111	E Koivunen, B Wang, E Ruoslahti (1995) Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 13:265–270 https://doi.org/10.1038/nbt0395-265
112	E Koivunen, W Arap, H Valtanen, A Rainisalo, OP Medina, P Heikkila, C Kantor, CG Gahmberg, T Salo, YT Konttinenet al. (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17:768–774 https://doi.org/10.1038/11703
113	MI Koukourakis, A Giatromanolaki, PE Thorpe, RA Brekken, E Sivridis, S Kakolyris, V Georgoulias, KC Gatter, AL Harris (2000) Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60:3088–3095
114	DN Krag, GS Shukla, GP Shen, S Pero, T Ashikaga, S Fuller, DL Weaver, S Burdette-Radoux, C Thomas (2006) Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res 66:7724–7733 https://doi.org/10.1158/0008-5472.CAN-05-4441
115	R Kumar, M Mandal, A Lipton, H Harvey, CB Thompson (1996) Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifeninduced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 2:1215–1219
116	H Kurahara, H Shinchi, Y Mataki, K Maemura, H Noma, F Kubo, M Sakoda, S Ueno, S Natsugoe, S Takao (2011) Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167:e211–e219 https://doi.org/10.1016/j.jss.2009.05.026
117	MK Kwon, JO Nam, RW Park, BH Lee, JY Park, YR Byun, SY Kim, IC Kwon, IS Kim (2008) Antitumor effect of a transducible fusogenic peptide releasing multiple proapoptotic peptides by caspase-3. Mol Cancer Ther 7:1514–1522 https://doi.org/10.1158/1535-7163.MCT-07-2009
118	P Laakkonen, K Porkka, JA Hoffman, E Ruoslahti (2002) A tumorhoming peptide with a targeting specificity related to lymphatic vessels. Nat Med 8:751–755 https://doi.org/10.1038/nm720
119	LA Landon, SL Deutscher (2003) Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem 90:509–517 https://doi.org/10.1002/jcb.10634
120	TY Lee, CT Lin, SY Kuo, DK Chang, HC Wu (2007) Peptidemediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 67:10958–10965 https://doi.org/10.1158/0008-5472.CAN-07-2233
121	ST Lee-Hoeflich, L Crocker, E Yao, T Pham, X Munroe, KP Hoeflich, MX Sliwkowski, HM Stern (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68:5878–5887 https://doi.org/10.1158/0008-5472.CAN-08-0380
122	JM Lehmann, G Riethmuller, JP Johnson (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 86:9891–9895 https://doi.org/10.1073/pnas.86.24.9891
123	Z Li, R Zhao, X Wu, Y Sun, M Yao, J Li, Y Xu, J Gu (2005) Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 19:1978–1985 https://doi.org/10.1096/fj.05-4058com
124	J Li, H Wang, J Li, J Bao, C Wu (2016) Discovery of a potential HER2 inhibitor from natural products for the treatment of HER2-Positive Breast cancer. Int J Mol Sci 17:E1055 https://doi.org/10.3390/ijms17071055
125	C Li, N Zhang, J Zhou, C Ding, Y Jin, X Cui, K Pu, Y Zhu (2018) Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res 6:178–188 https://doi.org/10.1158/2326-6066.CIR-17-0035
126	WJ Lin, LT Kao (2014) Cytotoxic enhancement of hexapeptideconjugated micelles in EGFR high-expressed cancer cells. Expert Opin Drug Deliv 11:1537–1550 https://doi.org/10.1517/17425247.2014.930433
127	M Lindgren, K Rosenthal-Aizman, K Saar, E Eiriksdottir, Y Jiang, M Sassian, P Ostlund, M Hallbrink, U Langel (2006) Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol 71:416–425 https://doi.org/10.1016/j.bcp.2005.10.048
128	X Liu, J Peng, J He, Q Li, J Zhou, X Liang, S Tang (2018) Selection and identification of novel peptides specifically targeting human cervical cancer. Amino Acids 50:577–592 https://doi.org/10.1007/s00726-018-2539-1
129	A Lo, CT Lin, HC Wu (2008) Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 7:579–589 https://doi.org/10.1158/1535-7163.MCT-07-2359
130	PS Low, WA Henne, DD Doorneweerd (2008) Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41:120–129 https://doi.org/10.1021/ar7000815
131	AJ Lyons, AC Bateman, A Spedding, JN Primrose, U Mandel (2001) Oncofetal fibronectin and oral squamous cell carcinoma. Br J Oral Maxillofac Surg 39:471–477 https://doi.org/10.1054/bjom.2001.0702
132	A Mantovani, F Marchesi, A Malesci, L Laghi, P Allavena (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14:399–416 https://doi.org/10.1038/nrclinonc.2016.217
133	H Margus, K Padari, M Pooga (2012) Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther 20:525–533 https://doi.org/10.1038/mt.2011.284
134	JS Marken, GL Schieven, I Hellstrom, KE Hellstrom, A Aruffo (1992) Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci U S A 89:3503–3507 https://doi.org/10.1073/pnas.89.8.3503
135	S Marqus, E Pirogova, TJ Piva (2017) Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci 24:21 https://doi.org/10.1186/s12929-017-0328-x
136	H Matsue, KG Rothberg, A Takashima, BA Kamen, RG Anderson, SW Lacey (1992) Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate. Proc Natl Acad Sci U S A 89:6006–6009 https://doi.org/10.1073/pnas.89.13.6006
137	C Medrek, F Ponten, K Jirstrom, K Leandersson (2012) The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12:306 https://doi.org/10.1186/1471-2407-12-306
138	J Mendelsohn, J Baselga (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787–2799 https://doi.org/10.1200/JCO.2003.01.504
139	G Menderes, E Bonazzoli, S Bellone, JD Black, S Lopez, F Pettinella, A Masserdotti, L Zammataro, B Litkouhi, E Ratneret al. (2017) Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Med Oncol 34:91 https://doi.org/10.1007/s12032-017-0956-8
140	P Mhawech, P Dulguerov, M Assaly, C Ares, AS Allal (2005) EB-D fibronectin expression in squamous cell carcinoma of the head and neck. Oral Oncol 41:82–88 https://doi.org/10.1016/j.oraloncology.2004.07.003
141	L Milas, K Mason, N Hunter, S Petersen, M Yamakawa, K Ang, J Mendelsohn, Z Fan (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701–708
142	S Miraglia, W Godfrey, AH Yin, K Atkins, R Warnke, JT Holden, RA Bray, EK Waller, DW Buck (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013–5021 https://doi.org/10.1182/blood.V90.12.5013
143	MC Morris, J Depollier, J Mery, F Heitz, G Divita (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19:1173–1176 https://doi.org/10.1038/nbt1201-1173
144	J Naidoo, DB Page, JD Wolchok (2014) Immune Checkpoint Blockade. Hematol Oncol Clin North Am 28:585–600 https://doi.org/10.1016/j.hoc.2014.02.002
145	MW Ndinguri, M Bhowmick, D Tokmina-Roszyk, TK Robichaud, GB Fields (2012) Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities. Molecules 17:14230–14248 https://doi.org/10.3390/molecules171214230
146	J Neuzil, M Stantic, R Zobalova, J Chladova, X Wang, L Prochazka, L Dong, L Andera, SJ Ralph (2007) Tumour-initiating cells vs. cancer ‘stem’ cells and CD133: what’s in the name? Biochem Biophys Res Commun 355:855–859 https://doi.org/10.1016/j.bbrc.2007.01.159
147	A Nishiyama, XH Lin, N Giese, CH Heldin, WB Stallcup (1996) Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. J Neurosci Res 43:315–330 https://doi.org/10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.0.CO;2-M
148	CA O’Brien, A Pollett, S Gallinger, JE Dick (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110 https://doi.org/10.1038/nature05372
149	MA Olayioye, RM Neve, HA Lane, NE Hynes (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167 https://doi.org/10.1093/emboj/19.13.3159
150	BG Ongarora, KR Fontenot, X Hu, I Sehgal, SD Satyanarayana-Jois, MG Vicente (2012) Phthalocyanine-peptide conjugates for epidermal growth factor receptor targeting. J Med Chem 55:3725–3738 https://doi.org/10.1021/jm201544y
151	MS O’Reilly, S Pirie-Shepherd, WS Lane, J Folkman (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926–1928 https://doi.org/10.1126/science.285.5435.1926
152	A Ouhtit, RL Gaur, ZY Abd Elmageed, A Fernando, R Thouta, AK Trappey, ME Abdraboh, HI El-Sayyad, P Rao, MG Raj (2009) Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta 1795:130–136 https://doi.org/10.1016/j.bbcan.2009.01.002
153	DM Pardoll (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264 https://doi.org/10.1038/nrc3239
154	J Park, S Kim, PE Saw, IH Lee, MK Yu, M Kim, K Lee, YC Kim, YY Jeong, S Jon (2012) Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging. J Control Release 163:111–118 https://doi.org/10.1016/j.jconrel.2012.08.029
155	J Park, S Park, S Kim, I-H Lee, PE Saw, K Lee, Y-C Kim, Y-J Kim, OC Farokhzad, YY Jeonget al. (2013) HER2-specific aptide conjugated magneto-nanoclusters for potential breast cancer imaging and therapy. J Mater Chem B 1:4576–4583 https://doi.org/10.1039/c3tb20613k
156	R Pasqualini, E Ruoslahti (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380:364–366 https://doi.org/10.1038/380364a0
157	R Pasqualini, E Koivunen, E Ruoslahti (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15:542–546 https://doi.org/10.1038/nbt0697-542
158	R Pasqualini, E Koivunen, R Kain, J Lahdenranta, M Sakamoto, A Stryhn, RA Ashmun, LH Shapiro, W Arap, E Ruoslahti (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60:722–727
159	M Prewett, J Huber, Y Li, A Santiago, W O’Connor, K King, J Overholser, A Hooper, B Pytowski, L Witteet al. (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209–5218
160	DJ Price, T Miralem, S Jiang, R Steinberg, H Avraham (2001) Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12:129–135
161	SM Pupa, S Menard, S Forti, E Tagliabue (2002) New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 192:259–267 https://doi.org/10.1002/jcp.10142
162	CN Qian, X Guo, B Cao, EJ Kort, CC Lee, J Chen, LM Wang, WY Mai, HQ Min, MH Honget al. (2002) Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62:589–596
163	D Rajotte, W Arap, M Hagedorn, E Koivunen, R Pasqualini, E Ruoslahti (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102:430–437 https://doi.org/10.1172/JCI3008
164	K Rasanen, A Vaheri (2010) Activation of fibroblasts in cancer stroma. Exp Cell Res 316:2713–2722 https://doi.org/10.1016/j.yexcr.2010.04.032
165	H Ren, C Gao, L Zhou, M Liu, C Xie, W Lu (2015) EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation. Drug Deliv 22:785–794 https://doi.org/10.3109/10717544.2014.896057
166	AL Ribeiro, OK Okamoto (2015) Combined effects of pericytes in the tumor microenvironment. Stem Cells Int 2015:868475 https://doi.org/10.1155/2015/868475
167	L Ricci-Vitiani, DG Lombardi, E Pilozzi, M Biffoni, M Todaro, C Peschle, R De Maria (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115 https://doi.org/10.1038/nature05384
168	MF Rimawi, R Schiff, CK Osborne (2015) Targeting HER2 for the treatment of breast cancer. Annu Rev Med 66:111–128 https://doi.org/10.1146/annurev-med-042513-015127
169	S Rizzo, G Attard, DL Hudson (2005) Prostate epithelial stem cells. Cell Prolif 38:363–374 https://doi.org/10.1111/j.1365-2184.2005.00356.x
170	S Rong, M Jeffers, JH Resau, I Tsarfaty, M Oskarsson, GF Vande Woude (1993) Met expression and sarcoma tumorigenicity. Cancer Res 53:5355–5360
171	S Rong, S Segal, M Anver, JH Resau, GF Vande Woude (1994) Invasiveness and metastasis of NIH 3T3 cells induced by Methepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A 91:4731–4735 https://doi.org/10.1073/pnas.91.11.4731
172	S Ropero, JA Menendez, A Vazquez-Martin, S Montero, H Cortes-Funes, R Colomer (2004) Trastuzumab plus tamoxifen: antiproliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 86:125–137 https://doi.org/10.1023/B:BREA.0000032981.20384.c6
173	JF Ross, PK Chaudhuri, M Ratnam (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73:2432–2443 https://doi.org/10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S
174	C Rouleau, DA Gianolio, R Smale, SD Roth, R Krumbholz, J Harper, KJ Munroe, TL Green, BC Horten, SM Schmidet al. (2015) Antiendosialin antibody–drug conjugate: potential in sarcoma and other malignancies. Mol Cancer Ther 14:2081–2089 https://doi.org/10.1158/1535-7163.MCT-15-0312
175	E Ruoslahti (2000) Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 10:435–442 https://doi.org/10.1006/scbi.2000.0334
176	E Ruoslahti (2003) The RGD story: a personal account. Matrix Biol 22:459–465 https://doi.org/10.1016/S0945-053X(03)00083-0
177	E Ruoslahti (2004) Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans 32:397–402 https://doi.org/10.1042/bst0320397
178	E Ruoslahti (2012) Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater 24:3747–3756 https://doi.org/10.1002/adma.201200454
179	J Ruschoff, W Hanna, M Bilous, M Hofmann, RY Osamura, F Penault-Llorca, M van de Vijver, G Viale (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25:637–650 https://doi.org/10.1038/modpathol.2011.198
180	L Ryden, B Linderholm, NH Nielsen, S Emdin, PE Jonsson, G Landberg (2003) Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82:147–154 https://doi.org/10.1023/B:BREA.0000004357.92232.cb
181	F Sallusto, M Cella, C Danieli, A Lanzavecchia (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182:389–400 https://doi.org/10.1084/jem.182.2.389
182	WB Saunders, BL Bohnsack, JB Faske, NJ Anthis, KJ Bayless, KK Hirschi, GE Davis (2006) Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol 175:179–191 https://doi.org/10.1083/jcb.200603176
183	PE Saw, S Kim, I-H Lee, J Park, M Yu, J Lee, J-I Kim, S Jon (2013) Aptide-conjugated liposome targeting tumor-associated fibronectin for glioma therapy. J Mater Chem B 1:4723–4726 https://doi.org/10.1039/c3tb20815j
184	PE Saw, J Park, E Lee, S Ahn, J Lee, H Kim, J Kim, M Choi, OC Farokhzad, S Jon (2015) Effect of PEG pairing on the efficiency of cancer-targeting liposomes. Theranostics 5:746–754 https://doi.org/10.7150/thno.10732
185	PE Saw, J Park, S Jon, OC Farokhzad (2017) A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin. Nanomedicine 13:713–722 https://doi.org/10.1016/j.nano.2016.10.005
186	RO Schlingemann, FJ Rietveld, RM de Waal, S Ferrone, DJ Ruiter (1990) Expression of the high molecular weight melanomaassociated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 136:1393–1405
187	FM Segers, H Yu, TJ Molenaar, P Prince, T Tanaka, TJ van Berkel, EA Biessen (2012) Design and validation of a specific scavenger receptor class AI binding peptide for targeting the inflammatory atherosclerotic plaque. Arterioscler Thromb Vasc Biol 32:971–978 https://doi.org/10.1161/ATVBAHA.111.235358
188	P Seshacharyulu, MP Ponnusamy, D Haridas, M Jain, AK Ganti, SK Batra (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15–31 https://doi.org/10.1517/14728222.2011.648617
189	K Shiga, M Hara, T Nagasaki, T Sato, H Takahashi, H Takeyama (2015) Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel) 7:2443–2458 https://doi.org/10.3390/cancers7040902
190	SC Shih, A Zukauskas, D Li, G Liu, LH Ang, JA Nagy, LF Brown, HF Dvorak (2009) The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. Cancer Res 69:3272–3277 https://doi.org/10.1158/0008-5472.CAN-08-4886
191	SK Singh, ID Clarke, M Terasaki, VE Bonn, C Hawkins, J Squire, PB Dirks (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828
192	SK Singh, C Hawkins, ID Clarke, JA Squire, J Bayani, T Hide, RM Henkelman, MD Cusimano, PB Dirks (2004) Identification of human brain tumour initiating cells. Nature 432:396–401 https://doi.org/10.1038/nature03128
193	GP Smith (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317 https://doi.org/10.1126/science.4001944
194	LM Smith, A Nesterova, MC Ryan, S Duniho, M Jonas, M Anderson, RF Zabinski, MK Sutherland, HP Gerber, KL Van Ordenet al. (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100 https://doi.org/10.1038/sj.bjc.6604437
195	S Song, D Liu, J Peng, Y Sun, Z Li, JR Gu, Y Xu (2008) Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm 363:155–161 https://doi.org/10.1016/j.ijpharm.2008.07.012
196	S Song, D Liu, J Peng, H Deng, Y Guo, LX Xu, AD Miller, Y Xu (2009) Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J 23:1396–1404 https://doi.org/10.1096/fj.08-117002
197	MD Sorensen, P Kristensen (2011) Selection of antibodies against a single rare cell present in a heterogeneous population using phage display. Nat Protoc 6:509–522 https://doi.org/10.1038/nprot.2011.311
198	PC Stapor, RS Sweat, DC Dashti, AM Betancourt, WL Murfee (2014) Pericyte dynamics during angiogenesis: new insights from new identities. J Vasc Res 51:163–174 https://doi.org/10.1159/000362276
199	JL Su, KP Lai, CA Chen, CY Yang, PS Chen, CC Chang, CH Chou, CL Hu, ML Kuo, CY Hsiehet al. (2005) A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res 65:4827–4835 https://doi.org/10.1158/0008-5472.CAN-05-0188
200	S Su, J Chen, H Yao, J Liu, S Yu, L Lao, M Wang, M Luo, Y Xing, F Chenet al. (2018) CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell 172:841–856.e816 https://doi.org/10.1016/j.cell.2018.01.009
201	S Suer, H Sonmez, I Karaaslan, H Baloglu, E Kokoglu (1996) Tissue sialic acid and fibronectin levels in human prostatic cancer. Cancer Lett 99:135–137 https://doi.org/10.1016/0304-3835(95)04084-6
202	J Sun, C Zhang, G Liu, H Liu, C Zhou, Y Lu, C Zhou, L Yuan, X Li (2012) A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro. Clin Exp Metastasis 29:185–196 https://doi.org/10.1007/s10585-011-9440-6
203	H Suzuki, M Sasada, S Kamiya, Y Ito, H Watanabe, Y Okada, K Ishibashi, T Iyoda, A Yanaka, F Fukai (2017) The promoting effect of the extracellular matrix peptide TNIIIA2 derived from tenascin-C in colon cancer cell infiltration. Int J Mol Sci 18:E181 https://doi.org/10.3390/ijms18010181
204	SD Sweat, A Pacelli, GP Murphy, DG Bostwick (1998) Prostatespecific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637–640 https://doi.org/10.1016/S0090-4295(98)00278-7
205	H Takayama, WJ LaRochelle, R Sharp, T Otsuka, P Kriebel, M Anver, SA Aaronson, G Merlino (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94:701–706 https://doi.org/10.1073/pnas.94.2.701
206	C Tang, BT Ang, S Pervaiz (2007) Cancer stem cell: target for anticancer therapy. FASEB J 21:3777–3785 https://doi.org/10.1096/fj.07-8560rev
207	T Tsunoda, H Inada, I Kalembeyi, K Imanaka-Yoshida, M Sakakibara, R Okada, K Katsuta, T Sakakura, Y Majima, T Yoshida (2003) Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol 162:1857–1867 https://doi.org/10.1016/S0002-9440(10)64320-9
208	T Tu, C Zhang, H Yan, Y Luo, R Kong, P Wen, Z Ye, J Chen, J Feng, F Liuet al. (2015) CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Res 25:275–287 https://doi.org/10.1038/cr.2015.15
209	PC Tumeh, CL Harview, JH Yearley, IP Shintaku, EJ Taylor, L Robert, B Chmielowski, M Spasic, G Henry, V Ciobanuet al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571 https://doi.org/10.1038/nature13954
210	T Ujula, M Huttunen, P Luoto, H Peräkylä, I Simpura, I Wilson, M Bergman, A Roivainen (2010) Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model. Bioconjug Chem 21:1612–1621 https://doi.org/10.1021/bc1000643
211	G Vauquelin, SJ Charlton (2013) Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol 168:1771–1785 https://doi.org/10.1111/bph.12106
212	A Visintin, K Knowlton, E Tyminski, CI Lin, X Zheng, K Marquette, S Jain, L Tchistiakova, D Li, CJ O’Donnellet al. (2015) Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. Mol Cancer Ther 14:1868–1876 https://doi.org/10.1158/1535-7163.MCT-15-0188
213	CF Waller, UM Martens, W Lange (1999) Philadelphia chromosomepositive cells are equally distributed in AC133+ and AC133-fractions of CD34+ peripheral blood progenitor cells from patients with CML. Leukemia 13:1466–1467 https://doi.org/10.1038/sj.leu.2401516
214	Z Wang, X Yan (2013) CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330:150–162 https://doi.org/10.1016/j.canlet.2012.11.049
215	J Wang, JJ Masehi-Lano, EJ Chung (2017) Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease. Biomater Sci 5:1450–1459 https://doi.org/10.1039/C7BM00271H
216	A Wells (1999) EGF receptor. Int J Biochem Cell Biol 31:637–643 https://doi.org/10.1016/S1357-2725(99)00015-1
217	N Wernert (1997) The multiple roles of tumour stroma. Virchows Arch 430:433–443 https://doi.org/10.1007/s004280050053
218	I Wierzbicka-Patynowski, JE Schwarzbauer (2003) The ins and outs of fibronectin matrix assembly. J Cell Sci 116:3269–3276 https://doi.org/10.1242/jcs.00670
219	GL Jr Wright, C Haley, ML Beckett, PF Schellhammer (1995) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1:18–28 https://doi.org/10.1016/1078-1439(95)00002-Y
220	CH Wu, IJ Liu, RM Lu, HC Wu (2016) Advancement and applications of peptide phage display technology in biomedical science. J Biomed Sci 23:8 https://doi.org/10.1186/s12929-016-0223-x
221	P Wulfing, C Kersting, H Buerger, B Mattsson, R Mesters, C Gustmann, B Hinrichs, J Tio, W Bocker, L Kiesel (2005) Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer 92:1720–1728 https://doi.org/10.1038/sj.bjc.6602567
222	J Xiao, A Burn, TJ Tolbert (2008) Increasing solubility of proteins and peptides by site-specific modification with betaine. Bioconjug Chem 19:1113–1118 https://doi.org/10.1021/bc800063k
223	L Xing, Y Xu, K Sun, H Wang, F Zhang, Z Zhou, J Zhang, F Zhang, B Caliskan, Z Qiuet al. (2018) Identification of a peptide for folate receptor alpha by phage display and its tumor targeting activity in ovary cancer xenograft. Sci Rep 8:8426 https://doi.org/10.1038/s41598-018-26683-z
224	X Yan, Y Lin, D Yang, Y Shen, M Yuan, Z Zhang, P Li, H Xia, L Li, D Luoet al. (2003) A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102:184–191 https://doi.org/10.1182/blood-2002-04-1004
225	H Yang, S Liu, H Cai, L Wan, S Li, Y Li, J Cheng, X Lu (2010) Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides. J Biol Chem 285:25666–25676 https://doi.org/10.1074/jbc.M109.089417
226	F Yang, W Ai, F Jiang, X Liu, Z Huang, S Ai (2016) Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: toxicity, Biodistribution, and Efficacy in Mice. J Pharm Sci 105:639–649 https://doi.org/10.1016/j.xphs.2015.10.020
227	Y Yarden, MX Sliwkowski (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137 https://doi.org/10.1038/35052073
228	Z Ye, C Zhang, T Tu, M Sun, D Liu, D Lu, J Feng, D Yang, F Liu, X Yan (2013) Wnt5a uses CD146 as a receptor to regulate cell motility and convergent extension. Nat Commun 4:2803 https://doi.org/10.1038/ncomms3803
229	AH Yin, S Miraglia, ED Zanjani, G Almeida-Porada, M Ogawa, AG Leary, J Olweus, J Kearney, DW Buck (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012 https://doi.org/10.1182/blood.V90.12.5002
230	D Yu, MC Hung (2000) Role of erbB2 in breast cancer chemosensitivity. BioEssays 22:673–680 https://doi.org/10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A
231	H Yu, M Kortylewski, D Pardoll (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51 https://doi.org/10.1038/nri1995
232	H Yu, D Pardoll, R Jove (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809 https://doi.org/10.1038/nrc2734
233	SS Yu, CM Lau, WJ Barham, HM Onishko, CE Nelson, H Li, CA Smith, FE Yull, CL Duvall, TD Giorgio (2013) Macrophage-specific RNA interference targeting via “click”, mannosylated polymeric micelles. Mol Pharm 10:975–987 https://doi.org/10.1021/mp300434e
234	P Yue, J Turkson (2009) Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18:45–56 https://doi.org/10.1517/13543780802565791
235	E Zanini, LS Louis, J Antony, E Karali, IS Okon, AB McKie, S Vaughan, M El-Bahrawy, J Stebbing, C Recchiet al. (2017) The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. Mol Cancer Ther 16:2246–2256 https://doi.org/10.1158/1535-7163.MCT-17-0081
236	Q Zhang, J Tang, L Fu, R Ran, Y Liu, M Yuan, Q He (2013) A pHresponsive alpha-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials 34:7980–7993 https://doi.org/10.1016/j.biomaterials.2013.07.014
237	P Zhao, T Grabinski, C Gao, RS Skinner, T Giambernardi, Y Su, E Hudson, J Resau, M Gross, GF Vande Woudeet al. (2007) Identification of a met-binding peptide from a phage display library. Clin Cancer Res 13:6049–6055 https://doi.org/10.1158/1078-0432.CCR-07-0035
238	C Zheng, Y Qiu, Q Zeng, Y Zhang, D Lu, D Yang, J Feng, X Yan (2009) Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol 41:2163–2172 https://doi.org/10.1016/j.biocel.2009.03.014
239	W Zhou, SQ Ke, Z Huang, W Flavahan, X Fang, J Paul, L Wu, AE Sloan, RE McLendon, X Liet al. (2015) Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol 17:170–182 https://doi.org/10.1038/ncb3090
240	W Zou, JD Wolchok, L Chen (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8:328rv4 https://doi.org/10.1126/scitranslmed.aad7118
241	AJ Zurita, W Arap, R Pasqualini (2003) Mapping tumor vascular diversity by screening phage display libraries. J Control Release 91:183–186 https://doi.org/10.1016/S0168-3659(03)00236-0

[1]	Boyi Zhang, Fei Chen, Qixia Xu, Liu Han, Jiaqian Xu, Libin Gao, Xiaochen Sun, Yiwen Li, Yan Li, Min Qian, Yu Sun. Revisiting ovarian cancer microenvironment: a friend or a foe?[J]. Protein Cell, 2018, 9(8): 674-692.
[2]	Yu Ping, Chaojun Liu, Yi Zhang. T-cell receptor-engineered T cells for cancer treatment: current status and future directions[J]. Protein Cell, 2018, 9(3): 254-266.
[3]	Fei Chen,Xinyi Qi,Min Qian,Yue Dai,Yu Sun. Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?[J]. Protein Cell, 2014, 5(11): 816-826.
[4]	Meng Xu, Xuexiang Du, Mingyue Liu, Sirui Li, Xiaozhu Li, Yang-Xin Fu, Shengdian Wang. The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody[J]. Prot Cell, 2012, 3(6): 441-449.
[5]	Ruth K. Moysey, Yi Li, Samantha J. Paston, Emma E. Baston, Malkit S. Sami, Brian J. Cameron, Jessie Gavarret, Penio Todorov, Annelise Vuidepot, Steven M. Dunn, Nicholas J. Pumphrey, Katherine J. Adams, Fang Yuan, Rebecca E. Dennis, Deborah H. Sutton, Andy D. Johnson, Joanna E. Brewer, Rebecca Ashfield, Nikolai M. Lissin, Bent K. Jakobsen. High affinity soluble ILT2 receptor: a potent inhibitor of CD8⁺ T cell activation[J]. Prot Cell, 2010, 1(12): 1118-1127.

Viewed

Full text

Abstract

Cited

Shared

Discussed